These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 31033862)
1. Clinical Monitoring Challenges in the Pharmacological Treatment and Management of Lymphatic Anomalies With Mammalian Target of Rapamycin Inhibition. Triana P; Miguel M; Díaz M; López-Gutierrez JC Ther Drug Monit; 2019 Aug; 41(4):547-548. PubMed ID: 31033862 [No Abstract] [Full Text] [Related]
2. [Inhibition of cell growth by rapamycin through targeting mammalian target of rapamycin signaling pathway in nasopharyngeal carcinoma]. Li YL; Zhang X; Liu Y; Li SS; Xie L; Zhang N; Liu XB; Tian YQ Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Sep; 45(9):765-8. PubMed ID: 21092676 [TBL] [Abstract][Full Text] [Related]
3. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Wei LH; Su H; Hildebrandt IJ; Phelps ME; Czernin J; Weber WA Clin Cancer Res; 2008 Jun; 14(11):3416-26. PubMed ID: 18519772 [TBL] [Abstract][Full Text] [Related]
4. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051 [TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Lang SA; Gaumann A; Koehl GE; Seidel U; Bataille F; Klein D; Ellis LM; Bolder U; Hofstaedter F; Schlitt HJ; Geissler EK; Stoeltzing O Int J Cancer; 2007 Apr; 120(8):1803-10. PubMed ID: 17230506 [TBL] [Abstract][Full Text] [Related]
6. Rapamycin: A promising agent to treat cancer pain? Jie D; Zhu B Int J Cancer; 2016 Oct; 139(7):1670-1. PubMed ID: 27244273 [No Abstract] [Full Text] [Related]
7. [Research advances in the mammalian target of rapamycin signaling pathway and its inhibitors in treatment of hepatocellular carcinoma]. Li SZ; Xu F; Sun CQ; Xu P Zhonghua Gan Zang Bing Za Zhi; 2018 Jan; 26(1):77-80. PubMed ID: 29804369 [TBL] [Abstract][Full Text] [Related]
8. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma. Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170 [TBL] [Abstract][Full Text] [Related]
9. Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review. Wiegand S; Wichmann G; Dietz A Lymphat Res Biol; 2018 Aug; 16(4):330-339. PubMed ID: 29924669 [TBL] [Abstract][Full Text] [Related]
10. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Pencreach E; Guérin E; Nicolet C; Lelong-Rebel I; Voegeli AC; Oudet P; Larsen AK; Gaub MP; Guenot D Clin Cancer Res; 2009 Feb; 15(4):1297-307. PubMed ID: 19190131 [TBL] [Abstract][Full Text] [Related]
11. Mammalian target of rapamycin inhibitors, temsirolimus and torin 1, attenuate stemness-associated properties and expression of mesenchymal markers promoted by phorbol-myristate-acetate and oncostatin-M in glioblastoma cells. Chandrika G; Natesh K; Ranade D; Chugh A; Shastry P Tumour Biol; 2017 Mar; 39(3):1010428317695921. PubMed ID: 28351321 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of mTOR enhances radiosensitivity of lung cancer cells and protects normal lung cells against radiation. Zheng H; Wang M; Wu J; Wang ZM; Nan HJ; Sun H Biochem Cell Biol; 2016 Jun; 94(3):213-20. PubMed ID: 26999331 [TBL] [Abstract][Full Text] [Related]
13. Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma. Gabor KM; Sapi Z; Tiszlavicz LG; Fige A; Bereczki C; Bartyik K Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28843050 [TBL] [Abstract][Full Text] [Related]
14. Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story? Geissler EK; Schnitzbauer AA; Schlitt HJ; Liver Transpl; 2016 Aug; 22(8):1162-3. PubMed ID: 27101937 [No Abstract] [Full Text] [Related]
16. Halcyon days of TOR: Reflections on the multiple independent discovery of the yeast and mammalian TOR proteins. Livi GP Gene; 2019 Apr; 692():145-155. PubMed ID: 30639424 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Huber S; Bruns CJ; Schmid G; Hermann PC; Conrad C; Niess H; Huss R; Graeb C; Jauch KW; Heeschen C; Guba M Kidney Int; 2007 Apr; 71(8):771-7. PubMed ID: 17299523 [TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin inhibitors in heart transplantation what we know and do not know? Zieliński T Int J Cardiol; 2018 Aug; 265():79-80. PubMed ID: 29885703 [No Abstract] [Full Text] [Related]
19. Mammalian Target of Rapamycin Inhibitors and Survival in Heart Transplant Recipients: Miracle or Mirage? Jennings DL; Lange N; Shullo M; Baker WL J Am Coll Cardiol; 2018 Jun; 71(24):2859-2860. PubMed ID: 29903356 [No Abstract] [Full Text] [Related]